• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    6/9/25 4:47:07 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    8-K
    INSULET CORP false 0001145197 0001145197 2025-06-06 2025-06-06
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 6, 2025

     

     

    INSULET CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-33462   04-3523891

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    100 Nagog Park, Acton, MA   01720
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (978) 600-7000

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 Par Value Per Share   PODD   The NASDAQ Stock Market, LLC

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    Credit Agreement Refinancing

    On June 6, 2025, Insulet Corporation (the “Company”) entered into the Eighth Amendment to Credit Agreement (the “Amendment”) with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the “Agent”), amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the “Credit Agreement”, and as amended by the Amendment, the “Amended Credit Agreement”), by and among the Company, the lenders and other parties thereto and the Agent.

    Pursuant to the Amendment, the $481,250,000 in aggregate principal amount of term loans outstanding under the Credit Agreement (the “Existing Term Loans”) were replaced with an equal amount of new term loans (the “New Term Loans”) having substantially similar terms as the Existing Term Loans, except with respect to the interest rate applicable to the New Term Loans and certain other provisions. Proceeds from the New Term Loans, together with cash on hand, were used to refinance the Existing Term Loans and pay accrued and unpaid interest thereon. In addition, the Company and its revolving facility lenders amended the Credit Agreement to reduce the interest rate margin applicable to revolving loans outstanding thereunder.

    The interest rate margin applicable to the New Term Loans is 1.00%, in the case of base rate loans, and 2.00%, in the case of term SOFR loans, with a SOFR floor of 0.00%. The interest rate margin applicable to the New Term Loans is 0.50% lower than the interest rate margin applicable to the Existing Term Loans. The New Term Loans were issued at par. The range of interest rate margins applicable to the revolving facility loans was reduced from 2.00% to 2.50% to 1.50% to 2.00% for term SOFR loans, with the interest rate margin applicable from time to time dependent upon the Company’s adjusted total leverage ratio (as defined in the Amended Credit Agreement). The SOFR floor applicable to revolving facility loans remains unchanged at 0.00%.

    The maturity of the revolving credit facility remains unchanged.

    The foregoing description of the Amendment is not intended to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

    Wachtell, Lipton, Rosen & Katz advised the Company in connection with the transactions.

    Unwind Agreements

    As previously disclosed, in connection with issuing the Convertible Notes (as defined below), the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions (the “Capped Call Counterparties”). In connection with the Company’s issuance of the Redemption Notice (as defined below), the Company entered into unwind agreements substantially in the form attached hereto as Exhibit 10.2, with each Capped Call Counterparty to terminate the Capped Call Transactions in full. In connection with the termination of these transactions, the Company expects the Capped Call Counterparties or their respective affiliates to unwind their related hedge positions, which may involve the sale of shares of the Company’s common stock in the open market or other transactions with respect to the Company’s common stock. This hedge unwind activity could offset the effects of the purchase activity that holders of the Convertible Notes being redeemed effected in connection with those transactions as described below.

    The above descriptions of the unwind agreements are a summary only and are qualified in their entirety by reference to the Form of Unwind Agreement, which is attached hereto as Exhibit 10.2, and is incorporated herein by reference.

     

    Item 1.02

    Termination of Material Definitive Agreement

    The information set forth under Item 1.01 relating to the termination of the Capped Call Transactions is hereby incorporated by reference into this Item 1.02.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03.

     

    Item 8.01

    Other Events.

    On June 9, 2025, the Company issued a notice of redemption (the “Redemption Notice”) for all of its outstanding 0.375% Convertible Senior Notes due 2026 (the “Convertible Notes” and the redemption thereof, the “Redemption”). Pursuant to the Redemption Notice, on August 20, 2025 (the “Redemption Date”), the Company will redeem any Convertible Notes that have not been converted, redeemed or repurchased prior to such date at a redemption price in cash equal to 100% of the principal amount of such Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date.

    In the event any holder of Convertible Notes converts its Convertible Notes prior to 5:00 p.m. (New York City time) on August 19, 2025 in accordance with the indenture governing such Convertible Notes, the Company intends to satisfy its conversion obligation


    with respect to such Convertible Notes in cash in accordance with such indenture. In connection with any conversion of Convertible Notes in connection with the Redemption, the Company expects that converting holders of the Convertible Notes who have hedged their equity price risk with respect to such Convertible Notes will unwind their hedge positions by buying the Company’s common stock and/or entering into or unwinding various derivative transactions with respect to the Company’s common stock.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

    The following exhibit is filed as part of this report:

     

    No.

      

    Exhibit

    10.1    Eighth Amendment to Credit Agreement, dated June 6, 2025, among Insulet Corporation, Insulet MA Securities Corporation, Morgan Stanley Senior Funding, Inc., as administrative agent, and the other lenders party thereto.
    10.2    Form of Unwind Agreement
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

     

        INSULET CORPORATION
    Date: June 9, 2025     By:  

    /s/ Ana M. Chadwick

          Ana M. Chadwick
          Executive Vice President, Chief Financial Officer

     

    Signature Page to 8-K

    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    12/21/2023$180.00 → $238.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Borio Luciana sold $147,056 worth of shares (481 units at $305.73), decreasing direct ownership by 13% to 3,087 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      6/10/25 4:17:19 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Director Weatherman Elizabeth H was granted 778 shares, increasing direct ownership by 17% to 5,242 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/27/25 4:14:43 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Director Stonesifer Timothy C. was granted 778 shares, increasing direct ownership by 27% to 3,629 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/27/25 4:13:12 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

      Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration represents a major milestone in our commitment to providing innovative solutions for diabetes manage

      6/10/25 8:30:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions throug

      5/23/25 6:01:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Announces Publication of 2024 Sustainability Report

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. "At Insulet, our sustainability impact is inextricably tied to our mission as a company and our workplace culture. Through our products and innovative business models, we can make life simpler for millions of people with diabetes while improving health outcomes," said Vice President of Global

      5/13/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PODD
    Financials

    Live finance-specific insights

    See more
    • Goldman initiated coverage on Insulet with a new price target

      Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

      5/30/25 8:41:35 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

      5/13/25 8:51:02 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet downgraded by Wolfe Research

      Wolfe Research downgraded Insulet from Outperform to Peer Perform

      4/29/25 8:07:24 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210

      4/3/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

      Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an

      2/20/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    SEC Filings

    See more
    • Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - INSULET CORP (0001145197) (Filer)

      6/9/25 4:47:07 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Insulet Corporation

      SD - INSULET CORP (0001145197) (Filer)

      5/29/25 4:02:08 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INSULET CORP (0001145197) (Filer)

      5/28/25 4:11:16 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      2/13/24 5:06:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care